New BARDA Award: NOWDiagnostics Inc. null Prod
Post# of 36537
(Total Views: 367)
Posted On: 08/31/2020 4:12:27 PM
New BARDA Award:
NOWDiagnostics Inc. null
Product Name: ADEXUSDx® COVID-19 Test
Description:
The ADEXUSDx® COVID-19 test is a rapid and accurate point of care lateral flow assay for detection of SARS-CoV-2 antibodies in blood that utilizes the NOWDiagnostics® ADEXUSDx® device platform. This platform is already commercialized for other tests, including an FDA cleared professional use pregnancy test that is CE marked for self-testing.
Unique Impact:
The ADEXUSDx® device platform allows direct application of a finger stick sample from the lance site to the test device without the need of an intermediate sample transfer step; removing the need for additional supplies (swabs, RNA isolation kits) that may be in short supply. The sample does not have to be sent to an off-site lab for analysis.
Base Award Amount: $695,500.00 (August 27, 2020)
Cost Share: Yes
NOWDiagnostics Inc. null
Product Name: ADEXUSDx® COVID-19 Test
Description:
The ADEXUSDx® COVID-19 test is a rapid and accurate point of care lateral flow assay for detection of SARS-CoV-2 antibodies in blood that utilizes the NOWDiagnostics® ADEXUSDx® device platform. This platform is already commercialized for other tests, including an FDA cleared professional use pregnancy test that is CE marked for self-testing.
Unique Impact:
The ADEXUSDx® device platform allows direct application of a finger stick sample from the lance site to the test device without the need of an intermediate sample transfer step; removing the need for additional supplies (swabs, RNA isolation kits) that may be in short supply. The sample does not have to be sent to an off-site lab for analysis.
Base Award Amount: $695,500.00 (August 27, 2020)
Cost Share: Yes
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼